Neuroprotection in acute ischemic stroke

Journal of Neurosurgical Sciences

Volumn 55, Issue 2, 2011, Pages 127-138

  Reza Noorian, A ^a   Nogueira, R G ^a   Gupta, R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Neurosurgery; Reperfusion; Stroke

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 PHOSPHONOMETHYLPIPECOLIC ACID; ALBUMIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APTIGANEL; BW 1003 C 87; BW 619 C 89; CAFFEINE; CAFFEINOL; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID; DEXTRORPHAN; DISUFENTON SODIUM; GAVESTINEL; GINKGO BILOBA EXTRACT; GROWTH FACTOR; LUBELUZOLE; MAGNESIUM ION; N [4 [4 [(3,4 DIHYDRO 6 HYDROXY 2,5,7,8 TETRAMETHYL 2H 1 BENZOPYRAN 2 YL)CARBONYL] 1 PIPERAZINYL]PHENYL] 2 THIOPHENECARBOXIMIDAMIDE; NALMEFENE; NALOXONE; NEUROTRANSMITTER; NIMODIPINE; PLACEBO; PROGESTERONE; ROVELIZUMAB; TIRILAZAD; TOPIRAMATE; UNCLASSIFIED DRUG; ZONAMPANEL;

ACUTE DISEASE; BLEEDING; BRAIN ISCHEMIA; EDEMA; HUMAN; HYPOTHERMIA; ISCHEMIC PRECONDITIONING; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SELECTION; REPERFUSION; REVIEW; TREATMENT OUTCOME;

ACUTE DISEASE; BRAIN ISCHEMIA; CEREBRAL REVASCULARIZATION; COMBINED MODALITY THERAPY; HUMANS; NEUROPROTECTIVE AGENTS; NEUROSURGICAL PROCEDURES; STROKE;

EID: 79960620428     PISSN: 00264881     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480-6.
2. Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology 2008;55:310-8.
3. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: A meta-analysis. Stroke 2007;38:967-73. (Pubitemid 46568460)
4. Baron JC. Perfusion thresholds in human cerebral ischemia: historical perspective and therapeutic implications. Cerebrovasc Dis 2001;11(Suppl. 1):2-8.
5. Heiss WD. Ischemic penumbra: evidence from functional imaging in man. J Cereb Blood Flow Metab 2000;20:1276-93.
6. Symon L, Branston NM, Strong AJ, Hope TD. The concepts of thresholds of ischaemia in relation to brain structure and function. J Clin Patho (R. Coll. Pathol.)1977;11:149-54.
7. Griepp RB, Ergin MA, McCullough JN, Nguyen KH, Juvonen T, Chang N et al. Use of hypothermic circulatory arrest for cerebral protection during aortic surgery. J Card Surg 1997;12(Suppl. 2):312-21.
8. Diener HC, Cortens M, Ford G, Grotta J, Hacke W, Kaste M et al. Lubeluzole in acute ischemic stroke treatment. A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke 2000;31:2543-51.
9. Jarvis CR, Anderson TR, Andrew D. Anoxic depolarization mediates acute damage independent of glutamate in neocortical brain slices. Cereb Cortex 2001;11:249-59. (Pubitemid 32199645)
10. Joshi I, Andrew RD. Imaging anoxic depolarization during ischemia-like conditions in the mouse hemi-brain slice. J Neurophysiol 2001;85:414-24. (Pubitemid 32062152)
11. Mehta SL, Manhas N, Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 2007;54:34-66. (Pubitemid 46498164)
12. Onteniente B, Rasika S, Benchoua A, Guegan C. Molecular pathways in cerebral ischemia. Cues to novel therapeutic strategies. Mol Neurobiol 2010;27:33-72.
13. Robinson MB. The family of sodium-dependent glutamate transporters: A focus on the GLT-1/EAAT2 subtype. Neurochem Int 1998;33:479-91. (Pubitemid 29116223)
14. Starkov AA, Chinopoulos C, Fiskum G. Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. Cell Calcium 2004;36:257-64. (Pubitemid 38992351)
15. Stankowski JN, Gupta R. Therapeutic Targets for Neuroprotection in Acute Ischemic Stroke: Lost in Translation? Antioxid Redox Signal 2011;14:1841-51.
16. Beere H, Green DR. Stress management-heat shock protein-70 and the regulation of apoptosis. Trends Cell Biol 2001;11:6-10. (Pubitemid 32056181)
17. Beere H. The stress of dying: The role of heat shock proteins in the regulation of apoptosis. J Cell Sci 2004;117:2641-51. (Pubitemid 38997248)
18. Polster BM, Kinnally KW, Fiskum G. Bh3 death domain peptide induces cell type-selective mitochondrial outer membrane permeability. J Biol Chem 2001;276:37887-94.
19. Kowaltowski AJ, Vercesi AE, Fiskum G. Bcl-2 prevents mitochondrial permeability transition and cytochrome c release via maintenance of reduced pyridine nucleotides. Cell Death Differ 2000;7:903-10.
20. Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D. Antioxidant therapy in acute central nervous system injury: Current state. Pharmacol Rev 2002;54:271-84. (Pubitemid 34575717)
21. Traystman RJ, Kirsch JR, Koehler RC. Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J Appl Physiol 1991;71:1185-95.
22. Iida H, Schmeichel AM, Wang Y, Schmelzer JD, Low PA. Orchestration of the inflammatory response in ischemia-reperfusion injury. J Peripher Nerv Syst 2007;12:131-8. (Pubitemid 46906335)
23. Labiche LA, Grotta JC. Clinical trials for cytoprotection in stroke. Neuro Rx 2004;1:46-70. (Pubitemid 46591882)
24. Grotta JC, Picone CM, Ostrow PT, Strong RA, Earls RM, Yao LP et al. CGS-19755, a competitive NMDA receptor antagonist, reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia. Ann Neurol 1990;27:612-9. (Pubitemid 20177408)
25. Steinberg GK, Perez-Pinzon MA, Maier CM et al. CGS-19755: correlation of in vitro neuroprotection, protection against experimental ischemia and CSF levels in cerebrovascular surgery patients. Abstract presented at Proceedings of the 5th International Symposium on Pharmacology of Cerebral Ischemia, Marburg, Germany, July 20-22, 1994.
26. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM. Safety, tolerability, and pharmacokinetics of the N-methyl-B-aspartate antagonist dextrorphan in patients with acute stroke. Stroke1995;26:254-8.
27. Albers GW, Goldstein LB, Hall D, Lesko LM for the Aptiganel Acute Stroke Investigators. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. JAMA 2001;21:2673-82. (Pubitemid 33135073)
28. Bordi F, Pietra C, Ziviani L, Reggiani A. The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat. Exp Neurol 1997;145:425-33. (Pubitemid 27314793)
29. Haley EC Jr, Thompson JL, Levin B, Davis S, Lees KR, Pittman JG et al. Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies. Stroke 2005;36:1006-10. (Pubitemid 40629293)
30. Warach S, Kaufman D, Chiu D, Devlin T, Luby M, Rashid A et al. Effect of the glycine antagonist gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: the GAIN MRI substudy. Cerebrovasc Dis 2005;21:106-11. (Pubitemid 43110319)
31. Kawasaki-Yatsugi S, Ichiki C, Yatsugi S, Takahashi M, Shimizu-Sasamata M, Yamaguchi T et al. Neuroprotective effects of an AMPA receptor antagonist YM872 in a rat transient middle cerebral artery occlusion model. Neuropharmacology 2000;39:211-7. (Pubitemid 30009815)
32. Suzuki M, Sasamata M, Miyata K. Neuroprotective effects of YM872 coadministered with t-PA in a rat embolic stroke model. Brain Res 2003;959:169-72. (Pubitemid 35435418)
33. Yang Y, Shuaib A, Li Q, Siddiqui MM. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res 1998;804:169-76. (Pubitemid 28496621)
34. Ying W, Anderson CM, Chen Y, Stein BA, Fahlman CS, Copin JC et al. Differing effects of copper, zinc superoxide dismutase overexpression on neurotoxicity elicited by nitric oxide, reactive oxygen species, and excitotoxins. J Cereb Blood Flow Metab 2000;20:359-68. (Pubitemid 30108455)
35. Murakami K, Kondo T, Kawase M, Li Y, Sato S, Chen SF et al. Mitochondrial susceptibility to oxidative stress exacerbates cerebral infarction that follows permanent focal cerebral ischemia in mutant mice with manganese superoxide dismutase deficiency. J Neurosci 1998;18:205-13. (Pubitemid 28046782)
36. Ford GA. Lubeluzole plasma concentrations and outcome in acute ischaemic stroke. Cerebrovasc Dis 2000;10:78 (abstr; Suppl 2).
37. Chabrier PE, Auguet M, Spinnewyn B, Auvin S, Cornet S, Demerle-Pallardy C et al. BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: A promising neuroprotective strategy. Proc Natl Acad Sci USA 1999;96:10824-9.
38. Bath P and Tirilazad International Steering Committee. Tirilazad mesylate in acute ischemic stroke: A systematic review. Stroke 2000;32:2257-65.
39. Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjö BK. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1999;19:778-87. (Pubitemid 30159804)
40. Lees KR, Barer D, Ford GA, Hacke W, Kostulas V, Sharma AK et al. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 2003;34:482-7. (Pubitemid 36206352)
41. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC et al. NXY-059 for acute ischemic stroke. NEJM 2006;354:588-600.
42. Savitz SI, Fisher M. Future of neuroprotection for acute stroke: In the aftermath of SAINT trials. Ann Neurol 2007;61:396-402.
43. Schneider D, Berrouschot J, Brandt T, Hacke W, Ferbert A, Norrie SH et al. Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): an open-label, dose escalation study in patients hospitalized for acute stroke. Eur Neurol 1998;40:78-83.
44. Yenari MA, Kunis D, Sun GH, Onley D, Watson L, Turner S et al. Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia. Exp Neurol 1998;153:223-33. (Pubitemid 28489889)
45. Del Zoppo GJ. Acute anti-inflammatory approaches to ischemic stroke. Ann NY Acad Sci 2010;1207:143-8.
46. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA et al. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003;34:2543-8. (Pubitemid 37392736)
47. Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psych 2005;76:1366-72. (Pubitemid 41360973)
48. Grotta JC. Clinical aspects of the use of calcium antagonists in cerebrovascular disease. Clin Neuropharmacol 1991;14:373-90.
49. The American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke. Stroke 1992;23:3-8.
50. Mohr JP, Orgogozo JM, Harrison M, Hennerici M, Wahlgren NG, Gelmers JH et al. Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 1994;4:197-203.
51. Horn J, de Haan RJ, Verneulen M, Limburg M. Very Early Nimodipine Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled trial. Stroke 2001;32:461-5. (Pubitemid 32155235)
52. Cross AF, Jones JA, Baldwin HA, Green AR. Neuroprotective activity of clomethiazole following transient forebrain ischemia in the gerbil. Br J Pharmacol 1991;104:406-11.
53. Marshall JWB, Cross AF, Murray TK, Ridley RM. Functional benefit from clomethiazole treatment after focal cerebral ischaemia in a non-human primate species (abstract). Stroke1998;29:330.
54. Wahlgren NG, Ranasinha KW, Rosolacci T, Franke CL, van Erven PM, Ashwood T et al.; for the CLASS Study Group. Clonethiazole Acute Stroke Study (CLASS): results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients. Stroke1999;30:21-8.
55. Davies MF, Deisz RA, Prince DA, Peroutka SJ. Two distinct effects of 5-hydroxytryptamine on single cortical neurons. Brain Res 1987;423:347-52. (Pubitemid 17157189)
56. Schaper C, Zhu Y, Kouklei M, Culmsee C, Krieglstein J. Stimulation of 5-HT1A receptors reduces apoptosis after transient forebrain ischemia in the rat. Brain Res 2000;883:41-50.
57. Ramirez-Lessepas M, Patrick BK, Snyder BD, Lakatua DJ. Failure of central nervous system serotonin blockage to influence outcome in acute cerebral infarction: a double-blind randomized trial. Stroke1986;17:953-6.
58. Teal P, Davis S, Hacke W, Kaste M, Lyden PD; Modified Randomized Exposure Controlled Trial Study Investigators. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT). Stroke 2009;40:3518-25.
59. Harini RJ, Supra EL, Roberts JP, Lavyne MH. Effect of naloxone on cerebral perfusion and cardiac performance during experimental cerebral ischemia. J Neurosurg 1986;64:780-6. (Pubitemid 16115357)
60. Namba S, Nishigaki S, Fujiwara N, Wani T, Namba Y, Masaoka T. Opiate-antagonist reversal of neurological deficits: experimental and clinical studies. Jpn J Psychiatry Neurol 1986;40:61-79.
61. Baskin DS, Juroda H, Hosobuchi Y, Lee NM. Treatment of Stroke with optiate antagonists - effects of exogenous antagonist and synorphin 1-13. Neuropeptides 1987;5:307-10. (Pubitemid 15141552)
62. Clark WM, Raps EC, Tong DC, Kelly RE, for the Cervene Stroke Study Investigators. Cervene (nalmefene) in acute ischemic stroke: final results of a phase III efficacy study. Stroke 2000;31:1234-9.
63. Muir KW. Magnesium in stroke treatment. Postgrad Med J 2002;78:641-5. (Pubitemid 36084162)
64. Lyden P, Wahlgren NG. Mechanisms of action of neuroprotectants in stroke. J Stroke Cerebrovasc Dis 2000;9(6 Pt 2):9-14.
65. Weglicki WB, Phillips TM. Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol (Lond)1992;263:R734- R7.
66. Yang Y, Li Q, Ahmad F, Shuaib A. Survival and histological evaluation of therapeutic window of post-ischemia treatment with magnesium sulfate in embolic stroke model of rat. Neurosci Lett 2000;285:119-22. (Pubitemid 30227634)
67. Muir KW, Lees KR, Ford I, Davis S; Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 2004;363:439-45.
68. Saver JL, Kidwell C, Eckstein M, Starkman S; FAST-MAG Pilot Trial Investigators. Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. Stroke 2004;35:e106-8.
69. Stein DG, Wright DW, Kellermann AL. Does progesterone have neuroprotective properties? Ann Emerg Med 2008;51:164-72.
70. Wright DW, Ritchie JC, Mullins RE, Kellermann AL, Denson DD. Steady-state serum concentrations of progesterone following continuous intravenous infusion in patients with acute moderate to severe traumatic brain injury. J Clin Pharmacol 2005;45:640-8. (Pubitemid 40696206)
71. Kobayashi T, Kuroda T, Tada M, Houkin K, Iwasaki Y, Abe H. Calcium-induced mitochondrial swelling and cytochrome c release in the brain: its biochemical characteristics and implication in ischemic neuronal injury. Brain Res 2003;960:62-70. (Pubitemid 36044563)
72. Loddick SA, MacKenzie A, Rothwell NJ. An ICE inhibitor, z-VAD-DCB attenuates ischaemic brain damage in the rat. Neuroreport 1996;7:1465-8.
73. Rami A, Agarwal R, Botez G, Winckler J. μ-Calpain activation, DNA fragmentation, and synergistic effects of caspase and calpain inhibitors in protecting hippocampal neurons from ischemic damage. Brain Res 2000;866:299-312.
74. Loh KP, Qi J, Tan BK, Liu XH, Wei BG, Zhu YZ. Leonurine protects middle cerebral artery occluded rats through antioxidant effect and regulation of mitochondrial function. Stroke 2010;41:2661-8.
75. Ginsberg MD, Palesch YY, Martin RH, Hill MD, Moy CS, Waldman BD et al. ALIAS Investigators. The albumin in acute stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2. Stroke 2011;42:119-27.
76. Palesch YY, Hill MD, Ryckborst KJ, Tamariz D, Ginsberg MD. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke. II. Neurological outcome and efficacy-analysis. Stroke 2006;37:2107-14.
77. Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 2002;8:58-61.
78. Jin KL, Mao XO, Goldsmith PC, Greenberg DA. CB1 cannabinoid receptor induction in experimental stroke. Ann Neurol 2000;48:257-61. (Pubitemid 30617047)
79. Ovadia H, Wohlman A, Mechoulam R, Weidenfeld J. Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat: relation to the adrenergic system and endogenous pyrogens. Neuropharmacology 1995;34:175-80.
80. Leker RR, Gai N, Mechoulam R, Ovadia H. Drug-induced hypothermia reduces ischemic damage. Effects of cannabinoid HU-210. Stroke 2003;34:2000-6.
81. Fernández-López D, Pradillo JM, García- Yébenes I, Martínez-Orgado JA, Moro MA, Lizasoain I. The cannabinoid WIN55212-2 promotes neural repair after neonatal hypoxia-ischemia. Stroke 2010;41:2956-64.
82. Murikinati S, Jüttler E, Keinert T, Ridder DA, Muhammad S, Waibler Z et al. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J 2010;24:788-98.
83. Gupta R, Jovin TG, Krieger DW. Therapeutic hypothermia for stroke: do new outfits change an old friend? Expert Rev Neurother 2005;5:235-46. (Pubitemid 40445145)
84. Chen Q, Chopp M, Bodzin G, Chen H. Temperature modulation of cerebral depolarization during focal cerebral ischemia in rats: Correlation with ischemic injury. J Cereb Blood Flow Metab 1993;13:389-94. (Pubitemid 23129391)
85. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;346:557-63. (Pubitemid 34438816)
86. The Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002;346:549-56.
87. Doerfler A, Schwab S, Hoffmann T, Engelhorn T, Forsting M. Combination of decompressive craniectomy and mild hypothermia ameliorates infarction volume after permanent focal ischemia in rats. Stroke 2001;32:2675-81. (Pubitemid 33055323)
88. Schwab S, Schwarz S, Spranger M, Keller E, Bertram M, Hacke W. Moderate hypothermia in the treatment of patients with severe middle cerebral artery infarction. Stroke 1998;29:2461-6. (Pubitemid 28543990)
89. Georgiadis D, Schwarz S, Aschoff A, Schwab S. Hemicraniectomy and moderate hypothermia in patients with severe ischemic stroke. Stroke 2002;33:1584-8. (Pubitemid 34619962)
90. Abou-Chebl A, DeGeorgia MA, Andrefsky JC, Krieger DW. Technical refinements and drawbacks of a surface cooling technique for the treatment of severe acute ischemic stroke. Neurocrit Care 2004;1:131-43. (Pubitemid 41278360)
91. De Georgia MA, Krieger DW, Abou-Chebl A, Devlin TG, Jauss M, Davis SM et al. Cooling for Acute Ischemic Brain Damage (COOL AID): a feasibility trial of endovascular cooling. Neurology 2004;63:312-7. (Pubitemid 38971132)
92. Hemmen TM, Raman R, Guluma KZ, Meyer BC, Gomes JA, Cruz-Flores S et al. Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results. Stroke 2010;41:2265-70.
93. Damian MS, Ellenberg D, Gildemeister R, Lauermann J, Simonis G, Sauter W et al. Coenzyme Q10 combined with mild hypothermia after cardiac arrest: a preliminary study. Circulation 2004;110:3011-6. (Pubitemid 39491991)
94. 7 receptor knockout mice. Proc Natl Acad Sci USA 2003;100:1375-80.
95. Zhao X, Strong R, Piriyawa P, Palusinski R, Grotta JC, Aronowski J. Caffeinol at the receptor level. Anti-ischemic effect of N-methyl-D-Aspartate receptor blockade is potentiated by caffeine. Stroke 2010;41:363-7.
96. Aronowski J, Strong R, Shirzadi A, Grotta JC. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke 2003;34:1246-51. (Pubitemid 36547523)
97. Piriyawat P, Labiche LA, Burgin WS, Aronowski JA, Grotta JC. Pilot dose-escalation study of caffeine plus ethanol (caffeinol) in acute ischemic stroke. Stroke 2003;34:1242-5. (Pubitemid 36547522)
98. Martin-Schild S, Hallevi H, Shaltoni H, Barreto AD, Gonzales NR, Aronowski J et al. Combined neuroprotective modalities coupled with thrombolysis in acute ischemic stroke: a pilot study of caffeinol and mild hypothermia. J Stroke Cerebrovasc Dis 2009;18:86-96.
99. Liu XQ, Sheng R, Qin ZH. The neuroprotective mechanism of brain ischemic preconditioning. Acta Pharmacol Sin 2009;30:1071-80.
100. Li J, Liu W, Ding S, Xu W, Guan Y, Zhang JH et al. Hyperbaric oxygen preconditioning induces tolerance against brain ischemia-reperfusion injury by upregulation of antioxidant enzymes in rats. Brain Res 2008;1210:223-9.
101. Traystman RJ, Kirsch JR, Koehler RC. Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J Appl Physiol 1991;71:1185-95.
102. Chaudhry K, Rogers R, Gui M, Lai Q, Goel G, Liebelt B et al. Matrix metalloproteinase-9 (MMP-9) expression and extracellular signal-regulated kinase 1 and 2 (ERK1/2) activation in exercise-reduced neuronal apoptosis after stroke. Neurosci Lett 2010;474:109-14.
103. Stowe AM, Altay T, Freie AB, Gidday JM. Repetitive hypoxia extends endogenous neurovascular protection for stroke. Ann Neurol Epub 2011 [Epub ahead of print].
104. Weih M, Kallenberg K, Bergk A, Dirnagl U, Harms L, Wernecke KD et al. Attenuated stroke severity after prodromal TIA: a role for ischemic tolerance in the brain? Stroke 1999;30:1851-4.
105. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D et al. from ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29.
106. Fink JN, Kumar S, Horkan C, Linfante I, Selim MH, Caplan LR et al. The stroke patient who woke up: Clinical and radiological features, including diffusion and perfusion MRI. Stroke 2002;33:988-93. (Pubitemid 34293580)
107. Kidwell CS, Alger JR, Saver JL. Evolving paradigms in neuroimaging of the ischemic penumbra. Stroke 2003;35:2662-5. (Pubitemid 39461995)
108. Bhatt A, Vora NA, Thomas AJ, Majid A, Kassab M, Hammer MD et al. Lower pretreatment cerebral blood volume affects hemorrhagic risks after intra-arterial revascularization in acute stroke. Neurosurgery 2008;63:874-8.
109. Gupta R, Yonas H, Gebel J, Goldstein S, Horowitz M, Grahovac SZ et al. Reduced pretreatment ipislateral middle cerebral blood flow is predictive of symptomatic hemorrhage post-intra-arterial thrombolysis in patients with middle cerebral artery occlusion. Stroke 2006;37:2526-30. (Pubitemid 44454673)
110. Jovin TG, Yonas H, Gebel JM, Kanal E, Chang YF, Gahovac SZ et al. The cortical ischemic core and the consistently present penumbra is a determinant of clinical outcome in acute middle cerebral artery occlusion. Stroke 2003;34:2426-33. (Pubitemid 37221955)
111. Mishra NK, Albers GW, Davis SM, Donnan GA, Furlan AJ, Hacke W et al. Mismatch-based delayed thrombolysis: A meta-analysis. Stroke 2010;41:e25-e33.
112. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1 026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-77.
113. [No authors listed]. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-8.